RxDoctor Payments Data

Houssam Mhanna, MD

Internal Medicine · Cleveland, OHNPI 1508105560

Payments from drug & device makers

$5,396in general payments, 2019–2025

Across 206 payments — averaging $26.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$784
  • Otsuka America Pharmaceutical, Inc.$598
  • Calliditas Therapeutics US Inc.$488
  • Bayer$376
  • Ardelyx, Inc.$342
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,21097%
  • Education$1863%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,396 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$366,783
Medicare patients
565
Services billed
2,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol127$155,694
VelphoroSucroferric Oxyhydroxide15$38,963
JardianceEmpagliflozin30$33,844
KerendiaFinerenone31$33,324
LokelmaSodium Zirconium Cyclosilicate38$30,796
Sevelamer Carbonate46$6,880
Midodrine Hcl47$3,885
ClinisolParenteral Amino Acid 15% No.519$3,609
Calcium Acetate49$2,749
Hydralazine Hcl144$1,630
Potassium Chloride71$970
Lisinopril194$956
Nifedipine ErNifedipine17$731
Amlodipine Besylate119$566
Losartan Potassium113$473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$784$186,490165 claims
Fresenius USA Marketing, Inc.Velphoro$341$38,96315 claims
Boehringer IngelheimJardiance$129$33,84430 claims
BayerKerendia$376$33,32431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →